RES-010

N/A

Report date: 2024/10/29 17:29:14
NMEFirst In Class

Base Information

Drug NameRES-010
Drug Alias NameRES-010
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionmicroRNA-22 modulators
TargetsmicroRNA-22
Therapy Area/IndicationsObesityMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesResalis Therapeutics SRL
China Registration ClassN/A

Develop Information

Active CompaniesResalis Therapeutics SRL
Inactive CompaniesN/A
Active IndicationsObesityMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A